List view / Grid view
Showing results for vaccine induced prothrombotic immune thrombocytopenia pathogenetic 20and epidemiological issues 20of concern vaccine induced vaccine-induced pathogenetic 20and issues 20of
5 May 2021 | By Giovanni Di Guardo DVM Dipl. ECVP
Giovanni Di Guardo, DVM, Dipl. ECVP, retired Veterinary Pathologist, discusses the association between adenoviral vector COVID-19 vaccines and rare blood clots, outlining four areas warranting further research.
15 September 2025 | By Dominic Tyer (European Pharmaceutical Review)
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
21 July 2020 | By Hannah Balfour (European Pharmaceutical Review)
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
26 May 2020 | By Hannah Balfour (European Pharmaceutical Review)
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
4 February 2021 | By Victoria Rees (European Pharmaceutical Review)
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
15 July 2015 | By Victoria White
Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...
15 September 2021 | By Anna Begley (European Pharmaceutical Review)
Johnson & Johnson’s Ebola vaccine regimen, Zabdeno® and Mvabea®, generated robust humoral immune responses in adults and children.
19 April 2021 | By Hannah Balfour (European Pharmaceutical Review)
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
24 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory diseases...
26 August 2013 | By Sanofi Pasteur
“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
9 September 2020 | By Hannah Balfour (European Pharmaceutical Review)
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
16 October 2020 | By
The Chinese COVID-19 vaccine candidate BBIBP-CorV elicited an antibody response in all recipients, according to preliminary Phase I/II trial data.
13 June 2023 | By Catherine Eckford (European Pharmaceutical Review)
If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.
6 March 2023 | By Catherine Eckford (European Pharmaceutical Review)
A National Institutes of Health (NIH)-supported trial has demonstrated the safety and efficiency of a freeze-dried thermostable tuberculosis vaccine.
